| Market Cap | ₹429.87 CrSmall Cap |
|---|---|
| P/E Ratio | 35.38Sector 48.58 |
| Promoter Holding | 64.91%No Pledges |
| 1Yr Price Change | 28.33%Annual Growth |
Key highlights
- In-principle approval granted for migration of 15,583,120 equity shares
- Approval pertains to shares with a face value of Rs 10 each
- Regulatory authorization remains valid for a period of 45 days
- Company must submit final listing application and agreement for trading commencement
- Migration follows a 49.17 percent annual growth in net profit for the previous fiscal year
Transition from SME Emerge to NSE Main Board
Infinium Pharmachem is moving from the NSE SME Platform (EMERGE) to the Main Board, a step that typically improves liquidity and broadens the investor base. The company reported annual operating revenue of ₹189.63 crore and a net profit of ₹12.15 crore for the last financial year. This migration path was formalised following shareholder approval via postal ballot on September 28, 2026.
The exchange's in-principle approval, valid for 45 days, requires the company to complete the formal listing application process before final trading permissions are granted on the Main Board.
Steps Toward Final Trading Approval
- Submission of the formal listing application to the National Stock Exchange
- Execution of the equity listing agreement as per exchange requirements
- Verification of compliance documents within the 45-day validity window
- Issuance of the final listing and trading notice by the exchange
- Migration of 1.55 crore equity shares to the Main Board trading system
Strategic Expansion and Sector Outlook
The pharmaceutical manufacturer has recently scaled its operations, including the commissioning of a contrast media raw materials facility at GIDC Sojitra on January 16, 2026. Management has previously shared a target of achieving ₹100 crore in annual revenue from the contrast media vertical over the next three years, with anticipated EBITDA margins of approximately 30 percent. Furthermore, the company is working toward a long-term goal of capturing a 25 percent market share in the Indian iodine market by 2030, supported by international distribution agreements like the five-year deal signed with Japan-based K Sakai & Company in June 2025.
| Date | Announcement | Amount |
|---|---|---|
| 06 Nov 2026 | Board approval of unaudited financial results for the half year ended 30 September 2026Source: NSE filing | – |
| 30 Sep 2026 | Submission of Annual Secretarial Compliance Report for migration from NSE Emerge to NSE Main BoardSource: NSE filing | – |
| 28 Sep 2026 | Approval by shareholders via Postal Ballot for migration of equity shares to the Main Board of NSESource: stocksigma.ai | – |
| 20 May 2026 | Resumption of manufacturing operations at GIDC Sojitra plant following GPCB revocation orderSource: millionshq.com | – |
| 16 Jan 2026 | Commissioning of contrast media raw materials manufacturing facility at GIDC SojitraSource: NSE filing | – |
| 26 Jun 2025 | Execution of 5-year exclusive distribution agreement with Japan-based K Sakai & CompanySource: NSE filing | – |
What to watch next
- Submission of the final listing application to NSE within the 45-day approval window
- Expansion of contrast media raw material production at GIDC Sojitra facility
- Progress toward the target of 25 percent Indian iodine market share by 2030
| Share price | ₹308.9 |
|---|---|
| Market capitalisation | ₹429.87 Cr |
| Revenue (annual) | ₹189.63 Cr |
| Net profit (annual) | ₹12.15 Cr |
| P/E (TTM) | 35.38×Sector 48.58× |
| Promoter holding | 64.91% |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Infinium Pharmachem Limited announcing receipt of in-principle approval for migration to the NSE Main Board. Market figures from a third-party data provider.



